CBIO compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

CBIOCrescent Biopharma, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

CBIOCrescent Biopharma, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only CBIO 5

CRLCharles River Laboratoriessupplier

—Paragon Therapeuticsunlistedsupplier

—WuXi Biologics (Hong Kong)unlistedsupplier

—WuXi Biologics Irelandunlistedsupplier

1 more · CBIO chain ›

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

CBIOCrescent Biopharma, Inc.

13.80▲+6.68%· post 13.28

Mkt cap$502.9MRevenue$1MQ1 FY26Revenue—

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

CBIOCrescent Biopharma, Inc.

LLYELI Lilly & Co

13.80▲+6.68%post 13.28

Price

1,360.90▼−0.28%post 1,358.90

$502.9M

Mkt cap

$1.2T

Q1 FY26$1M

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

CBIO13.80▲+6.68%vsLLY1,360.90▼−0.28%ClosedNov 6 '26